Results 111 to 120 of about 3,722,377 (405)

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Problem diagnostic of Krukenberg tumor

Majalah Obstetri dan Ginekologi, 2019
Objectives: to report the case of Krukenberg tumor in 57 years old woman, with complaints of abdominal enlargement since the last 10 months. Case Report: a 57 years old woman, multipara, post menopause, came to our hospital with complaints of enlarging ...
Reza Wangsanagara, Pungky Mulawardhana, Vicky Sumarki, Anny Setijo Rahaju, Tri Wulanhandarini   +4 more
doaj   +1 more source

EIF5A2 controls ovarian tumor growth and metastasis by promoting epithelial to mesenchymal transition via the TGFβ pathway

Cell & Bioscience, 2021
Background Epithelial to mesenchymal transition (EMT) contributes to tumor metastasis and chemoresistance. Eukaryotic initiation factor 5A2 (EIF5A2) is highly expressed in a variety of human cancers but rarely expressed in normal tissues.
Guannan Zhao, Wenjing Zhang, Peixin Dong, Hidemichi Watari, Yuqi Guo, Lawrence M. Pfeffer, Gabor Tigyi, Junming Yue   +7 more
doaj   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Multimodal Magnetic Resonance and Near-Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode-Dual-Gadolinium Liposomal Contrast Agent. [PDF]

, 2016
The degree of tumor removal at surgery is a major factor in predicting outcome for ovarian cancer. A single multimodality agent that can be used with magnetic resonance (MR) for staging and pre-surgical planning, and with optical imaging to aid surgical ...
Annapragada, A, Anvari, B, Bankson, J, Bhavane, R, Kundra, V, Ravoori, MK, Singh, S, Sood, AK   +7 more
core   +2 more sources

A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer

Nature Communications, 2017
Paclitaxel (PTX) is among the most commonly used first-line drugs for cancer chemotherapy. However, its poor water solubility and indiscriminate distribution in normal tissues remain clinical challenges.
Fangfei Li, Jun Lu, Jin Liu, C. Liang, Maolin Wang, Luyao Wang, Defang Li, Houzong Yao, Qiulong Zhang, J. Wen, Zongkang Zhang, Jie Li, Quanxia Lv, Xiaojuan He, B. Guo, Daogang Guan, Yuanyuan Yu, L. Dang, Xiaohao Wu, Yongshu Li, Guofen Chen, Feng Jiang, Shiguo Sun, Bao-Ting Zhang, Aiping Lu, Ge Zhang   +25 more
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Ovarian vein sampling, and serum and urine testosterone monitoring in ovarian Leydig cell tumors: A report of two cases

Case Reports in Women's Health, 2020
Background: Ovarian Leydig cell tumors are rare, testosterone-producing tumors that pose diagnostic challenges. Cases: A 36-year-old woman presented with 10 years of amenorrhea, facial hair growth and clitoromegaly.
Grace Whiteley, Olivia Carpinello, Micah J. Hill, Alan DeCherney   +3 more
doaj   +1 more source

Ovarian Endometrioid Adenocarcinomas With Infiltrative “Adenofibroma-like” Morphology and Aberrant ß-catenin Expression: Tumors That Coexpress CDX2 and LEF1 With Frequent Neuroendocrine Marker Expression, Diminished/Lost PAX8 and Possible Association With Endometrioid Type II Stem Cell Outgrowths in the Fallopian Tube [PDF]

, 2023
Jin Xu, Stephanie M. McGregor, Kay J. Park, Paul Weisman   +3 more
openalex   +1 more source

A Multi-Modality Ovarian Tumor Ultrasound Image Dataset for Unsupervised Cross-Domain Semantic Segmentation

arXiv.org, 2022
Qi Zhao, Shuchang Lyu, W. Bai, Linghan Cai, Binghao Liu, Mei-Hsuan Wu, Xiubo Sang, Min Yang, Lijiang Chen   +8 more
semanticscholar   +1 more source